Roche
Manufacturing · Switzerland · 103,605 Employees
View Company Info for Free
About
Headquarters
124 Grenzacherstrasse, Basel, Basel-City, 4070,...Phone Number
+41 616881111Website
www.roche.comRevenue
$71.1 BillionStock Symbol
ROIndustry
Most Recent Scoops
Who is Roche
Roche Org Chart
Is Roche your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Roche has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Roche recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Roche
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Roche has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Roche launches new products
Check out if Roche is spiking on competitors!
Click to see if Roche had a recent Job posting/layoffs
Roche, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Roche
Compare insights from companies similar to Roche, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Roche
Compare CEO
How does Severin Schwan compare against Competing Companies' CEOs?

Severin Schwan
CEO at Roche
CEO effectiveness to drive business results
VS.

Emma Walmsley
CEO at GSK
CEO effectiveness to drive business results

Emma Walmsley
CEO at GSK

Albert Bourla
CEO at Pfizer

Norman Schwartz
CEO at Bio-Rad
Roche Email Formats
Roche uses at least 5 email formats with first.last (ex. John.Smith@roche.com) being used 75.3% of the time
Roche Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@roche.com | 75.3% |
first + last | JohnSmith@roche.com | |
first_last | John_Smith@roche.com | |
first | John@roche.com | |
last | Smith@roche.com |
Get Verified Emails
Roche Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Roche Tech Stack
A closer look at the technologies used by Roche
Most Recent Scoops
Roche News & Media
Some May Be Optimistic About Roche Holding's (VTX:ROG) Earnings
The market for Roche Holding AG's ( VTX:ROG ) shares didn't move much after it posted weak earnings recently. We did...New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
Basel, 7 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published in the New England Journal of Medicine.1 The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of complete renal response (CRR), showing that 46.4% of people treated with Gazyva/Gazyvaro plus standard therapy (mycophLegacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group
Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, a member of the Roche Group. This strategic acquisition underscores Legacy Pharma's commitment to [PR.com]Radiopharma Advancell raises $112M in series C for alpha therapies | BioWorld
Aussie radiopharma company Advancell Co. Ltd. closed an oversubscribed $112 million series C round that will accelerate clinical development of its pipeline of radionuclide therapies and allow it to expand its manufacturing capacity.
Frequently Asked Questions Regarding Roche
For more than 125 years, Roche has worked to improve the health of countless people all over the world. With the trust of our shareholders and guided by scientific progress, we will continue to identify and seize opportunities well into the future.... Read More